Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Centro di Salute Globale, Università Cattolica del Sacro Cuore, Rome, Italy.
Pediatric Clinic, Pietro Barilla Children's Hospital, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Int J Infect Dis. 2023 May;130 Suppl 1:S16-S19. doi: 10.1016/j.ijid.2023.03.023. Epub 2023 Mar 21.
The spread of drug-resistant tuberculosis (TB) encouraged the development of new medicines and the reappraisal of old drugs rarely used in recent years. Providing access for children with drug-resistant TB to appropriate treatments is a cornerstone of strategies to reduce the burden of TB worldwide. Aim of this perspective was to describe the availability of child-friendly medicines to treat drug-resistant TB at the global level. We showed that the development of child-friendly formulations of second-line drugs should be encouraged to promote adherence to recommended treatment regimens and consequently to increase the success rate and to prevent the development of additional mycobacterial resistances. This is even more crucial, considering the long duration of antitubercular therapies. Importantly, companies and policy makers are called to more efforts in facilitating their prompt availability in every contest because drug-resistant pediatric TB is a worldwide medical problem.
耐多药结核病（TB）的传播促使人们开发新的药物，并重新评估近年来很少使用的旧药物。为耐多药结核病儿童提供适当的治疗方法是全球范围内减少结核病负担的策略的基石。本观点旨在描述全球范围内可用于治疗耐多药结核病的儿童友好型药物的供应情况。我们表明，应鼓励开发二线药物的儿童友好型制剂，以促进遵守推荐的治疗方案，从而提高成功率并防止产生更多的分枝杆菌耐药性。考虑到抗结核治疗的持续时间较长，这一点更为关键。重要的是，需要公司和政策制定者做出更多努力，以便在任何情况下都能更方便地获得这些药物，因为耐多药儿科结核病是一个全球性的医学问题。
